The appearance on the market of amoxicillin, protected by clavulanic acid, which is produced by one of the domestic leaders in the production of antibacterial drugs, is difficult to overestimate, because antibiotics are one of the main classes of medicines without which modern medicine is simply inconceivable. At the same time, despite the fact that the nomenclature of this class of drugs today includes a very wide spectrum, humanity will always need new antibacterial drugs. The reason for this is the ability of microorganisms to develop resistance (resistance) to antibiotics.
One of the most specific defense mechanisms in microorganisms is the inactivation of antimicrobial agents by β-lactamase enzymes, which are capable of destroying penicillins and cephalosporins. Such a defense mechanism uses Staphylococcus aureus, haemophilus influenzae, Moraxella catarrhalis, E. coli, Escherichia coli, Klebsiella pneumoniae, gram-negative rods of Bacteroides fragilis. These are the main pathogens of infectious and inflammatory diseases of various organs and systems.
Alas, the ability of microbes to resist is progressing. So, back in 1956, Lawrence Garrod and Pamela Waterworth, in the article “Antibiotics versus Staphylococci”, noted that one of the most important problems of modern medical practice in hospitals is the widespread prevalence of staphylococcus aureus Infections resistant to antibiotics. However, even after half a century, little has changed in this respect: the resistance of microorganisms to antibiotics continues to be a scourge of antibiotic therapy. Researchers make a less than comforting conclusion: the formation of a number of resistant strains of pathogenic bacteria is inevitable. At the same time, some of them had resistance to all classes of antimicrobial agents. Obviously, this not only negates all the efforts of developers of antibacterial drugs, but also puts humanity before a serious threat to become, in the end, practically defenseless against bacterial infection.
In order to overcome resistance, researchers, in the course of a long study, obtained compounds that are able to inactivate the enzymes of β-lactamase, which were given the name because of their ability to destroy the β-lactam ring of this class of drugs. One such inhibitor, clavulanic acid, was synthesized in the early 1970s. This compound has a β-lactam structure similar to that of penicillins, which allows it to bind to penicillin-binding proteins of Gram-positive and Gram-negative bacteria and promote lysis of the bacterial wall. As a result, clavulanic acid exhibits activity in relation to clinically important plasmid β-lactamases, which are often responsible for the occurrence of cross-resistance to antibiotics. In addition, this property of clavulanate allows it to also display its own antibacterial activity.
By combining clavulanic acid with an antibiotic such as amoxicillin, a fundamentally new drug with a set of special effects has been obtained. Irreversibly blocking β-lactamase, clavulanic acid opens the path for amoxicillin to attack, allowing it to exhibit its entire set of properties: a wide range of antibacterial activity; High bioavailability even when administered orally (not destroyed by acidic gastric juice, eating does not affect the absorption of the drug); And, as a consequence, the ability to create high concentrations of active substance in tissues and body fluids that effectively fight microorganisms.
Few people know that thanks to the amoxicillin + clavulanic acid complex it is possible not only to enhance the antibacterial action of the antibiotic, but also to increase the intracellular bactericidal activity of human leukocytes. This activity of antimicrobial immunity increases both with respect to strains of bacteria producing and not producing b-lactamase (Finlay J., Miller L., Poupard J.A., 2003).
All these properties of the amoxicillin + clavulanate complex allow the drug AMOXIL to show high clinical efficacy in many infections of various organs and systems that do not change over time.
The application of the drug AMOXYL is surprising in its breadth, because it shows a high bactericidal effect on both gram-positive and gram-negative aerobic and anaerobic flora. Therefore, this drug can be taken as a monotherapy even in those cases when it would be necessary to use therapy with the combination of two or more antibiotics. Due to this the doctor, on the one hand, has the ability to influence the incidence of adverse reactions, and on the other hand, does not give microorganisms a chance to develop stable strains. In addition, ASMOXIL-K allows one of the most important tasks of antibiotic therapy – to destroy bacteria in the focus of infection, that is, to achieve their full eradication: only this ensures the absence of a relapse or chronic disease.
The above set of qualities of the drug AMOXIL allows you to recommend it when:
- Infections of the upper and lower respiratory tract (tonsillitis, sinusitis, otitis media, exacerbation of chronic bronchitis, pneumonia)
- Infections of the genitourinary system (cystitis, urethritis, pyelonephritis, sexually transmitted infections, gynecological and obstetrical infections)
- Infectious lesions of the skin and soft tissues, bones and joints (osteomyelitis)
- With the aim of perioperative prevention of surgical infection.
Moreover, along with a wide spectrum of action and high efficiency, which (as shown by the long experience of using the amoxicillin + clavulanic acid complex) persists for a long time, AMOXIL has a favorable safety profile as well as good tolerance. The latter circumstance allows the use of AMOXIL-K in children; Patients with concomitant pathology; Elderly patients, who, as a rule, have age-related disorders from the liver and kidneys.
Obviously, due to the appearance of the drug AMOXIL for parenteral and oral administration, which otherwise can not be called a good antibiotic, the therapy of various infections has become even more accessible to patients, and our concern for them and the opportunity to help is even closer.